Bossard (BOSN) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
3 Feb, 2026Executive summary
Achieved satisfactory H1 2024 results despite an 11.7% sales decline and challenging economic conditions, with some stabilization in Q2 and strong growth in India.
Profitability supported by improved gross profit margin of 33.3% and cost reductions through efficiency and digitalization.
Benefited from new opportunities in electronics, semiconductor, and aerospace sectors, especially in India and Benelux after the acquisition of Dejond Fastening.
Successful rollout of new ERP/digital platforms in France and South Africa; ongoing digitalization investments.
Acquisition of Dejond Fastening NV in Belgium and full ownership of bigHead Fasteners Ltd in the UK expanded market presence.
Financial highlights
H1 2024 net sales reached CHF 509.4 million, down 11.7% year-over-year, with currency effects negatively impacting results.
Gross profit margin improved to 33.3% from 32% last year.
EBIT decreased 16.6% to CHF 58.1 million; EBIT margin at 11.4% (vs. 12.1%).
Net income declined to CHF 42.4 million from CHF 49.9 million; return on sales at 8.3%.
Free cash flow was CHF 30.9 million, reflecting higher acquisition outflows.
Outlook and guidance
Persistent uncertainty expected due to unsettled economic environment, geopolitical tensions, and trade conflicts.
Cautious optimism for 2024, supported by a robust project pipeline, focus on sunrise industries, and digitalization.
Midterm targets: organic sales growth >5%, EBIT margin 12–15%, equity ratio >40%, dividend payout ratio at 40% of net income.
CapEx for 2024 expected at CHF 34–36 million, with higher spending in H2.
Moderate economic demand and a slightly higher cost base anticipated for H2 2024.
Latest events from Bossard
- 2025 sales up 8.6% as sunrise industries and digitalization offset FX and market headwinds.BOSN
H2 20255 Mar 2026 - 2025 sales rose 8.6% to CHF 1,068.9m, with 10% EBIT margin guidance reaffirmed.BOSN
Q4 2025 TU15 Jan 2026 - Sales fell 7.7% but margins, cash flow, and growth investments remained strong.BOSN
H2 202423 Dec 2025 - Strategic initiatives and digitalization target >5% growth, margin recovery, and market leadership.BOSN
CMD 202522 Nov 2025 - Sales rose 7.6% to CHF 547.9 million, but net income and free cash flow declined on higher costs.BOSN
H1 202516 Nov 2025 - Q3 2025 sales rose 10.2% year-over-year, with full-year sales forecasted at CHF 1,055–1,065 million.BOSN
Q3 2025 TU14 Oct 2025